Malm Maria, Uusi-Kerttula Hanni, Vesikari Timo, Blazevic Vesna
Vaccine Research Center, University of Tampere Medical School.
Vaccine Research Center, University of Tampere Medical School Department of Pediatrics, Tampere University Hospital, Finland.
J Infect Dis. 2014 Dec 1;210(11):1755-62. doi: 10.1093/infdis/jiu361. Epub 2014 Jun 26.
Norovirus is a common cause of acute gastroenteritis in children. Serum immunoglobulin G (IgG) antibodies have been implicated in protection against norovirus-associated gastroenteritis, but the level, specificity, and functionality necessary for protection remain to be elucidated.
Norovirus-specific IgG antibodies to genogroup II (GII)-4-2010 New Orleans (NO), GII-4-1999, GII-12-1998, GI-1-2001, and GI-3-2002 virus-like particles (VLPs) were determined by enzyme-linked immunosorbent assay in serum samples collected from children who presented to the hospital because of acute norovirus gastroenteritis in 2009-2011. The blocking activity of the antibodies was tested in a surrogate neutralization assay.
Most norovirus infections (62.8%) in the study population were caused by a GII-4 NO variant. Children who acquired GII-4 NO infection had a low preexisting type-specific IgG level and blocking activity of the sera, in contrast to children infected with other GII genotypes. Following GII-4 NO infection, genotype-specific seroconversion and a corresponding increase in blocking antibody potential was observed. Although seroconversion to the heterologous GII-4-1999 variant was observed, there was no corresponding increase in the specific blocking antibody titer. There was no concomitant seroconversion against GI VLPs, indicating a highly genogroup-specific antibody response.
High preexisting norovirus genotype-specific serum IgG titers and blocking activity in children indicate protection from norovirus infection in a strain-specific manner.
诺如病毒是儿童急性胃肠炎的常见病因。血清免疫球蛋白G(IgG)抗体与预防诺如病毒相关性胃肠炎有关,但保护所需的水平、特异性和功能仍有待阐明。
采用酶联免疫吸附试验,对2009 - 2011年因急性诺如病毒胃肠炎入院的儿童血清样本中针对II型(GII)-4-2010新奥尔良(NO)、GII-4-1999、GII-12-1998、GI-1-2001和GI-3-2002病毒样颗粒(VLP)的诺如病毒特异性IgG抗体进行测定。在替代中和试验中检测抗体的阻断活性。
研究人群中大多数诺如病毒感染(62.8%)由GII-4 NO变异株引起。与感染其他GII基因型的儿童相比,感染GII-4 NO的儿童既往存在的型特异性IgG水平和血清阻断活性较低。GII-4 NO感染后,观察到基因型特异性血清转化以及相应的阻断抗体潜力增加。尽管观察到向异源GII-4-1999变异株的血清转化,但特异性阻断抗体滴度没有相应增加。未观察到针对GI VLP的伴随血清转化,表明抗体反应具有高度的基因型特异性。
儿童中预先存在的高诺如病毒基因型特异性血清IgG滴度和阻断活性表明以菌株特异性方式预防诺如病毒感染。